News

10 Aug 2017

Nicola Sturgeon: interview at the official opening of REPROCELL's Centre for Predictive Drug Discovery (YouTube video)

First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.
Read More >>

13 May 2016

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.
Read More >>

21 Apr 2016

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).
Read More >>

25 Nov 2015

Biopta to be acquired by Japanese stem cell company ReproCELL

Biopta is to be acquired by the stem cell and regenerative medicine company ReproCELL. The deal will help Biopta to expands its range of drug discovery services based on human fresh tissues.
Read More >>

1 2 3 4 >>

Visit REPROCELL Stand H2 at ELRIG Drug Discovery 2017 Conference, 3-4 October 2017

15/09/2017

The ELRIG Drug Discovery 2017 Conference will be held at the Arena and Conference Centre (ACC) in Liverpool, UK, on 3-4 October 2017. See https://elrig.org/portfolio/elrig-2017-events-programme/.

 

REPROCELL will be at stand H2 at the Vendor Exhibition, which is located in ACC Hall 2.

 

Present from REPROCELL Europe Ltd will be:

  • Dr David Bunton – CEO REPROCELL Europe Ltd (founder of Biopta Ltd, now part of REPROCELL Europe)
  • Dr Frederique Tholozan – Research Scientist and Technical Support Specialist
  • Chirag Tawde – Sales Director EMEA
  • Anca Haralambie – Business Development and Distributor Sales Representative

 

About REPROCELL

REPROCELL is a global biotech company specializing in stem cell technologies, providing one of the world’s largest biorepositories of human cell, DNA and RNA samples, 2D and 3D cell culture products, induced pluripotent stem cells (iPSCs), and expert contract research services using live human tissue. Our integrated workflow covers every step of the drug discovery process used in biotech and pharma companies and institutions around the world. As a global technology partner, REPROCELL has the history, expertise and flexibility to accelerate your research.

 

  • The latest RNA reprogramming technology
  • Fresh human tissue assays tailored to your needs
  • Prospective bio specimen collection for e.g. gene and protein analysis, iPSC generation
  • Cutting edge and personalized 3D cell-based assays

 

About Elrig Drug Discovery 2017

From http://elrig.org/portfolio/drug-discovery-2017-elrigdd17/:

 

Drug Discovery is ELRIG’s flagship event. Now in its 11th year, we return to ACC in Liverpool to bring together the leading lights in drug discovery research across pharma, biotech, academia and the vendor community.

 

The meeting will feature over 50 world-class speakers in 6 main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success. This conference will explore innovative technologies and approaches that can be used to overcome drug development challenges, and bring together industry leaders who will discuss future opportunities for novel therapeutic discovery. Scientific tracks will cover:

 

  • Innovations in Chemistry
  • Target Identification and Validation
  • Innovations in Assay Design, Development and Screening
  • Advances in Imaging
  • Drug Discovery in the 4th Dimension
  • From Molecule to Man: Right dose, first time

 

There will also be a series of vendor workshops, which will provide a more informal, interactive environment for you to discuss key issues and future directions in workshops coordinated by leaders in the fields. Drug Discovery 2017 will include a high quality scientific poster session, networking opportunities, and an extensive vendor exhibition featuring around 100 companies. And don’t miss the Innovation Zone, for new and exciting emerging companies and technologies.

 

Plenary keynote speakers

 

Dr. Mene Pangalos (Executive Vice-President, IMED Biotech Unit, AstraZeneca)
Dr. Nessa Carey (International Director at PraxisUnico, Visiting Professor at Imperial College, and author)

 

If you would like REPROCELL to visit you in the Liverpool area

If you would like to arrange a face to face meeting with one of our experts in around the dates that we are in the Liverpool area, about any of our services and products, please email Anca on anca.haralambie@reprocell.com.

Visit REPROCELL Booth 107 at the SPS Annual Meeting, Berlin, 24-27 September 2017

15/09/2017

This year’s Safety Pharmacology Society (SPS) Annual Meeting will be held in the Maritim Hotel, Berlin, Germany, on 24-27 September 2017. See http://www.safetypharmacology.org/am2017/program.asp.

 

REPROCELL will be at booth 107.

 

Present from REPROCELL Europe Ltd will be:

  • Chirag Tawde – Sales Director EMEA
  • Dr Graeme Macluskie – “Meet the Expert” REPROCELL Europe Ltd head of R&D.

 

Dr Graeme Macluskie is an expert in the development, implementation and validation of new tissue assays to address clinical safety, efficacy, ADME and toxicology during the early drug discovery process.

 

Take part in our Competition

Guess the number of rice grains in our culture media bottle and you could win a set of 2 specially engraved REPROCELL whisky glasses, 1 bottle Scottish whisky and 1 bottle of Japanese whisky.

 

About REPROCELL

REPROCELL is a global biotech company specializing in stem cell technologies, providing one of the world’s largest biorepositories of human cell, DNA and RNA samples, 2D and 3D cell culture products, induced pluripotent stem cells (iPSCs), and expert contract research services using live human tissue. Our integrated workflow covers every step of the drug discovery process used in biotech and pharma companies and institutions around the world. As a global technology partner, REPROCELL has the history, expertise and flexibility to accelerate your research.

 

  • The latest RNA reprogramming technology
  • Fresh human tissue assays tailored to your needs
  • Prospective bio specimen collection for e.g. gene and protein analysis, iPSC generation
  • Cutting edge and personalized 3D cell-based assays

 

About the SPS Annual Meeting

Highlights of the Annual Meeting 2017:

 

  • A dynamic forum for best practice sharing within industry, CRO’s, academics and regulators
  • Scientific Sessions organized by SPS Members
  • Sessions on some of the hottest topics in safety pharmacology related research
  • 6 CE Courses taught by experts in the field
  • Plenary Keynote Speakers by a key opinion leaders
  • Exhibit hall offering access to industry vendors
  • Poster sessions featuring cutting-edge research
  • Networking opportunities with a global community of scientists from regulatory, industry, and academia
  • Award opportunities to bring together Student and Jr. Investigators with seasoned scientists, while sharing their research
  • Exhibitor Sponsored Sessions by leading technology and service providers showcasing their new offerings and research

 

http://www.safetypharmacology.org/am2017/.

 

About the SPS

The Safety Pharmacology Society is a nonprofit organization that promotes knowledge, development, application, and training in Safety Pharmacology—a distinct scientific discipline that integrates the best practices of pharmacology, physiology and toxicology. The objective of Safety Pharmacology studies is to further the discovery, development and safe use of biologically active chemical entities by the identification, monitoring and characterization of potentially undesirable pharmacodynamic activities in nonclinical studies. The Safety Pharmacology Society also supports the human safety of drugs and biologicals by fostering scientific research, education, and dissemination of scientific information through meetings and other scientific interactions.

 

The Society is committed to uniting the global safety pharmacology community in the development and safe medical use of biologically active molecular entities by bridging across disciplines to allow the identification, characterization, and monitoring of potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials.

 

http://www.safetypharmacology.org/am2017/.

Live chat by BoldChat